Looking for Investment, Acquisition, Partnerships or Collaborations?
Hosting AbbVie, AZ, Biogen, J&J, Merck, Sanofi, Regeneron, Otsuka, and UCB, the Autoimmunity Pharma & Biotech Partnering Summit guarantees 30-minute, in-person meetings, to foster scientific partnerships across targeted cell depletion and immune tolerance.
Helping both biotech and pharma cut through the noise to enhance portfolios, drive external collaboration, and promote creative partnerships across early-stage innovation; this unique initiative is an intensely valuable 48 hours for business development across immunology.
EVENT IN NUMBERS
attending companies across modalities so pharma can decide which horse to back in this quickly evolving space
big pharma leads across business development, search and evaluation, immunology research and venture giving the best, most comprehensive opportunity to meet the full teams assessing due diligence and asset synergy
meetings bookable via the partnering portal for efficient and high yielding conversations between decision makers
alignment on interests and intentions, increasing the surface area for synergy in research and collaboration goals
Testimonials
Key Figures from Partnering Series
meetings through the partnering portal
acceptance rate of meetings, versus 11% industry standard
total attendees, including: 23 pharma, 65 biotech
companies, including: 16 pharma, 58 biotech, 4 investors
C-level, 57% Vice President or Above, 94% Director or above
Event Attendees
For biotech business development and corporate strategy
to collaborate together across modalities with potential for combinations, or co-develop with pharma to combine resources and confidently progress past proof-of-concept.
For pharma search and evaluation, business development, and corporate venture
to compare competing and complementary science across modalities in the context of scientific discussion, direct ongoing early development of high potential assets, and grow activity or pipelines in the hotly anticipated immune reset and reconstitution field.